May 28 (Reuters) - Johnson & Johnson ( JNJ ) said on
Tuesday that it had agreed to acquire the rights to an
experimental skin disorder treatment from privately held Numab
Therapeutics for about $1.25 billion.
J&J will acquire Numab's unit for the global rights to the
drug, called NM26.
(Reporting by Christy Santhosh in Bengaluru; Editing by Anil
D'Silva)